# GALLIUM (NCT01332968)

> A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

No report yet. It can be ordered.

- Drugs tested: obinutuzumab
- Indication: previously untreated advanced indolent non-Hodgkin lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01332968
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Non-Hodgkin's Lymphoma
- Interventions: Obinutuzumab; Cyclophosphamide; Doxorubicin; Vincristine; Prednisone; Bendamustine; Rituximab
- Enrollment: 1401
- Primary outcome: Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed

## Questions raised in the commentary

_Automated from the 40 newest of 65 indexed sources (Jan 2021 – Sep 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether obinutuzumab should be preferred over rituximab
- Whether maintenance is needed after induction, and for whom
- How to weigh obinutuzumab's potential benefit against toxicity
- Whether reducing POD24 leads to better long-term outcomes

Also discussed: bone health.

## Indexed commentary on GALLIUM so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 43
- YouTube: 11
- Podcasts: 11

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=gallium-nct01332968

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01332968", "email": "<work email>"}; the inbox owner confirms by the emailed link.